# NCT02927301 (NCT02927301)

> A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Resectable Non-Small Cell Lung Cancer (NSCLC) - Lung Cancer Mutation Consortium (LCMC3)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02927301
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Genentech, Inc.
- Conditions: Non-Small Cell Lung Cancer
- Interventions: Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
- Enrollment: 181
- Primary outcome: Percentage of Participants With Major Pathologic Response (MPR)

## Commentary we found

- X threads: 8
- YouTube: 6
- Podcasts: 3

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=nct02927301

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02927301", "email": "<work email>"}; the inbox owner confirms by the emailed link.